Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Adaptive Biotechnologies highlighted an NCCN update adding a dedicated page for measurable residual disease (MRD) testing in multiple myeloma, signaling that the guideline panel views MRD assessment as essential to patient management. The guidelines recommend use of an FDA-approved assay such as Adaptive's clonoSEQ or flow-based testing, a potentially meaningful validation that could support broader clinical adoption and demand for clonoSEQ.

Analysis

The key transmission mechanism is not simply incremental test volume, but a lower-friction path from specialist preference to standardized ordering behavior. A dedicated guideline workflow can improve hospital formulary adoption, payer prior-authorization outcomes, and recurring longitudinal utilization; those effects matter more to ADPT's revenue durability than one-time new-patient testing. The near-term market reaction may be modest because guideline language does not itself establish reimbursement or clinician compliance, but it raises the probability that management can support stronger utilization commentary over the next 1-3 quarters.

Competitive risk is asymmetric: broad flow-cytometry testing remains entrenched and can be cheaper or more accessible at academic centers, while laboratory-developed alternatives may retain share where turnaround time or local contracting dominates. ADPT's advantage depends on converting clinical specificity into operational switching costs, particularly through repeat monitoring; failure to show sequential test-volume acceleration would imply that the guideline change is informational rather than economically material. The most important verification points are commercial payer coverage expansion, ordering-provider growth, average tests per monitored patient, and whether gross margin improves with laboratory scale.

Consensus may overfocus on the clinical endorsement while underweighting the sales-cycle lag. Guideline incorporation can take 6-18 months to move through institutional pathways, and multi-myeloma treatment innovation could create either more monitoring demand or fragmented testing protocols. The thesis is falsified if the next two earnings reports show no improvement in test-volume growth or if management declines to quantify conversion, reimbursement, or repeat-order metrics attributable to the updated workflow.

Key Decisions for Investors

• Initiate only a small, catalyst-driven long ADPT over the next 1-3 months, preferably after confirming post-guideline ordering traction in quarterly metrics; target a 10-15% position-level upside versus a 7-10% stop if utilization and revenue guidance do not improve.
• Use a long ADPT / short XBI pair for investors seeking to isolate company-specific execution from biotech beta; reassess after the next two earnings releases, with exit if ADPT does not demonstrate accelerating clonoSEQ volume or improved commercial-payer access.
• Do not underwrite a large multiple expansion solely on the guideline development. Set an alert for quantified updates on repeat testing, payer wins, and gross-margin progression; absent those data, treat the development as a watch item rather than a structural earnings revision.
• Monitor flow-cytometry and MRD testing competitors, including NeoGenomics (NEO) and major academic laboratory channels, for pricing or turnaround-time responses; aggressive discounting would weaken ADPT's ability to translate higher clinical visibility into operating leverage.